13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: Immunogenicity and safety

Pediatric Infectious Disease Journal

Volumn 31, Issue 4, 2012, Pages 392-399

  Martinón Torres, Federico ^a   Gimenez Sanchez, Francisco ^b   Gurtman, Alejandra ^c   Bernaola, Enrique ^d   Diez Domingo, Javier ^e   Carmona, Alfonso ^f   Sidhu, Mohinder ^c   Sarkozy, Denise A ^c   Gruber, William C ^c   Emini, Emilio A ^c   Scott, Daniel A ^c  

^a Santiago University Clinical Hospital   (Spain)

^b Unidad de Gestión Clínica Cirugía y Area de Gestión Norte de Almería   (Spain)

^c PFIZER INC   (United States)

^d Universidad Pública de Navarra   (Spain)

^e Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^f Instituto Hispalense de Pediatria   (Spain)

Author keywords

infants; meningococcal vaccination; pneumococcal vaccination; Streptococcus pneumoniae

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; MENINGOCOCCAL SEROGROUP C TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFECTION; INFESTATION; IRRITABILITY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROTYPE; SIDE EFFECT; SKIN MANIFESTATION; SLEEP; SWELLING;

ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID; VACCINATION; VACCINES, CONJUGATE;

EID: 84858800419     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824b972b     Document Type: Review

References (38)

1. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
2. European Medicines Agency. European Public Assessment Report (EPAR) summary for the public, 2011. Prevenar. Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000323/ WC500041558.pdf. Accessed November 4, 2011.
3. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
4. Pérez-Trallero E, Marimon JM, Ercibengoa M, et al. Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2009;28:731-738.
5. GAVI's PneumoADIP. GSP Summary Report (Stage 1; Version 1) for SAGE meeting November 6-8, 2007; October 18, 2007 Version (Public Use Document). Pneumococcal Global Serotype Project Summary report of Stage 1/Version 1 analysis. Available at: http://www.preventpneumo.org/pdf/ GSP%20Summary%20for%20SAGE%20Nov6-8%202007-Oct%2019-07.pdf. Accessed November 4, 2011.
6. Kieninger DM, Kueper K, Steul K, et al.; 006 study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192-4203.
7. Yeh SH, Gurtman A, Hurley DC, et al.; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493-e505.
8. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017-1026.
9. Bernaola Iturbe E, Giménez Sánchez F, Baca Cots M, et al.; Asociación Española de Pediatría. [Vaccination schedule of the Spanish association of pediatrics: recommendations 2009]. An Pediatr (Barc). 2009;70:72-82.
10. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4:156-167. (Pubitemid 27130227)
11. Quataert SA, Rittenhouse-Olson K, Kirch CS, et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin Diagn Lab Immunol. 2004;11:1064-1069. (Pubitemid 39540845)
12. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816-3826. (Pubitemid 46589754)
13. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23:2222-2227. (Pubitemid 40341456)
14. Christenson B, Böttiger M. Serological immunity to diphtheria in Sweden in 1978 and 1984. Scand J Infect Dis. 1986;18:227-233. (Pubitemid 16081860)
15. MacLennan R, Schofield FD, Pittman M, et al. Immunization against neonatal tetanus in New Guinea. Antitoxin response of pregnant women to adjuvant and plain toxoids. Bull World Health Organ. 1965; 32:683-697.
16. World Health Organization. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser. 2005;927:1-154.
17. Vanderkooi OG, Scheifele DW, Girgenti D, et al.; for the Canadian PCV13 Study Group. Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada. Pediatr Infect Dis J. 2012;31:72-77.
18. Diez-Domingo J, Gurtman A, Bernaola E, et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers receiving routine vaccinations in Spain. Pediatr Infect Dis J. 2009;28:e167-e168.
19. Gimenez-Sanchez F, Kieninger DM, Kueper K, et al.; 501 and 006 study groups. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:6042-6048.
20. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29:e80-e90.
21. Wysocki J, Tansey S, Brachet E, et al. Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines. Vaccine. 2010;28:7779-7786.
22. Knuf M, Habermehl P, Cimino C, et al. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine. 2006;24:4727-4736. (Pubitemid 43776787)
23. Olivier C, Belohradsky BH, Stojanov S, et al. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine. 2008;26:3142-3152.
24. Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009;28(suppl 4):S97-S108.
25. Buttery JP, Riddell A, McVernon J, et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA. 2005;293:1751-1758.
26. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101(4 Pt 1):604-611. (Pubitemid 28180141)
27. Ekström N, Ahman H, Verho J, et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun. 2005;73:369-377. (Pubitemid 40041129)
28. Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J. 2010;29:756-762.
29. Bryant KA, Block SL, Baker SA, et al.; PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125:866-875.
30. Payton T, Girgenti D, Frenck R, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States. Presented at: 7th International Symposium on Pneumococci and Pneumococcal Diseases, March 14-18, 2010, Tel Aviv, Israel. Abstract 199.
31. Kaye P, Malkani R, Martin S, et al. Invasive pneumococcal disease in England & Wales after 7-valent conjugate vaccine; potential impact of 10 and 13-valent vaccines. Presented at: 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID), Brussels, Belgium, June 9-13, 2009.
32. Kaye P, Andrews N, Slack M, George R, Miller E. Vaccine effectiveness and indirect protection from pneumococcal conjugate vaccine used in a 2-dose infant priming plus booster schedule in England and Wales. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Disease, Reykjavik, Iceland; 2008. Poster P3-118.
33. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008;26:3277-3281.
34. Deceuninck G, De Wals P, Boulianne N, et al. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J. 2010;29:546-549.
35. Durando P, Crovari P, Ansaldi F, et al.; Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine. 2009;27:3459-3462.
36. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:9127-9131.
37. Fenoll A, Aguilar L, Giménez MJ, et al. Susceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine. Antimicrob Agents Chemother. 2010;54:2696-2698.
38. Muñoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174-182. (Pubitemid 351269154)